

A hormetic approach to understanding antidepressant effectiveness and the development of antidepressant tolerance – A conceptual view

Paul W. Andrews¹, Jay D. Amsterdam²

¹Department of Psychology, Neuroscience & Behaviour,
McMaster University, Hamilton, Ontario, Canada

²Depression Research Unit, Department of Psychiatry,
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

Summary

Antidepressants such as the selective serotonin reuptake inhibitors (SSRIs) have complex temporal effects. They may worsen symptoms during early treatment, they may reduce depressive symptoms over several weeks of treatment, and they may lose effectiveness over more prolonged treatment or after repeated treatment trials. Conceptually, these effects fall within the domain of hormesis, which refers to a biphasic or multiphasic response to a drug or toxin. Hormetic effects are commonly triggered when a drug interacts with homeostatic mechanisms. We develop and evaluate a theoretical framework for understanding how adaptations to SSRIs that restore synaptic homeostasis may partially contribute to their hormetic effects. Specifically, the serotonin system adapts to SSRIs by suppressing the firing of serotonergic neurons, inhibiting the synthesis of serotonin, and reducing the overall content of serotonin in the brain. Moreover, rodent models such as inescapable shock show that serotonin neurotransmission to specific forebrain regions is a necessary, but insufficient cause of depressive symptoms. Our review suggests: (1) early worsening of symptoms may be related to the direct effects of SSRIs on synaptic serotonin; (2) the symptom-reducing effects could be related to the loss of serotonin content in the brain during SSRI exposure; (3) the loss of efficacy over prolonged exposure could be related to the central nervous system equilibrating to the SSRIs. The serotonin system's adaptations to SSRIs may play a clinically meaningful role in their hormetic effects on depressive symptoms. A complete understanding of SSRIs' hormetic effects will require exploring temporal dynamics in other neurotransmitter systems.

Key words: adaptation, antidepressants, hormesis, oppositional tolerance, tachyphylaxis, stepwise resistance

Introduction

The hypothesis that depression is caused by low levels of monoamines, particularly norepinephrine [1] and serotonin [2, 3], was proposed more than 50 years ago. While the low monoamine hypothesis has been very influential, there has been no consistent support for this hypothesis from either animal or human studies [4–6]. The low monoamine hypothesis was largely based on evidence that certain drugs had depression-reducing effects and they caused synaptic levels of monoamines to increase [5, 6]. However, a long-recognized problem with this hypothesis is the fact that antidepressant drugs have complex and puzzling temporal effects on depressive symptoms (Table 1).

Table 1. Predicted or observed effects of SSRIs on various parameters as a function of the phase of treatment

Parameter	Phase						
	Premedication Baseline	SSRI Treatment			Discontinuation		
		Acute	Chronic	Prolonged	Acute	Chronic	Prolonged
Depressive symptoms	—	↑* (early worsening)	↓*	—* (return of symptoms)	↓	↑* (rebound or relapse)	—
Extracellular 5-HT	—	↑*	—*	—	↓*	—	—
Total brain 5-HT	—	—	↓*	↓	↓*	—	—
5-HT neuron firing	—	↓*	—*	—	↑	—	—
5-HT synthesis	—	↓*	↓*	↓	↑*	—	—
5-HIAA/5-HT	—	↓*	↓*	↓	↑*	↑*	—

All parameters in the premedication phase are set to “—”, and effects in the other phases are relative to the premedication baseline. Because antidepressants lose efficacy over multiple bouts of treatment (see text), these patterns assume that the organism is medication naïve. An asterisk denotes an effect that is empirically supported (see text for details).

For instance, the selective serotonin reuptake inhibitors (SSRIs) increase synaptic serotonin within minutes to hours of administration [7, 8], but they do not usually produce clinically significant reductions in depressive symptoms except over several weeks of chronic treatment—a phenomenon called the *therapeutic delay* [9, 10]. In fact, some individuals may experience a worsening of symptoms during early (acute) SSRI treatment [11–13]. Over the course of more prolonged treatment (months or years) antidepressants may lose effectiveness [14, 15], which is sometimes referred to as *tachyphylaxis* [16, 17]. Relatedly, antidepressants may lose effectiveness after repeated treatment trials (*stepwise resistance*). Thus, antidepressants that were effective during prior depressive episodes may be less effective in treating new episodes [18–22]. In contrast, repeated antidepressant treatment trials may not diminish the response to future psychotherapy [23]. Finally, the likelihood of depressive relapse is high after discontinuation of long-term antidepressant therapy [14, 24], and higher than after discontinuation of psychotherapy [25].

We currently lack a mechanistic understanding of how antidepressants interact with the central nervous system (CNS) to produce these complex temporal effects. While the multiphasic effects of SSRIs have been puzzling to pharmacologists and neuroscientists, they fall within the domain of hormesis. *Hormesis* refers to the biphasic or multiphasic effects that a drug or toxin has on a biological parameter as a function of the dose or the duration of exposure [26–29]. For instance, chemicals that inhibit the growth of organisms at high concentrations often stimulate growth at low concentrations [30]. Psychotropic drugs often produce hormetic responses in receptor systems [31], and antidepressants often have biphasic effects on diverse biological parameters over acute and chronic treatment (Table 2).

Table 2. **Biphasic effects of antidepressants (AD) in response to acute treatment (single dose) and chronic treatment relative to the control condition (set to “—”)**

Trait	AD	Animal	Control	Acute	Chronic	Refs
Aggression	Multiple classes	Rats	—	↓	↑	[120]
Anxiety	Citalopram	Humans	—	↑	↓	[90,121]
BDNF expression	Fluoxetine, desipramine	Rats	—	↓	↑	[122,123]
Microtubule structure	Fluoxetine	Rats	—	↑	↓	[124]
Potentialiation of temporoammonic-CA1 synapse	Fluoxetine, citalopram, imipramine	Rats, mice	—	↑	↓	[125]
Excitability of motor cortex	Paroxetine	Humans	—	↑	↓	[126,127]

With the exception of BDNF expression, the data for each trait come from the same laboratory.

Hormetic responses are widespread in nature, and they are more common than linear dose responses [28, 32]. The multiphasic effects of SSRIs are not surprising when viewed from the lens of the hormesis literature, since hormetic responses tend to be the rule rather than the exception.

Hormetic responses are not limited to particular chemical agents, environmental or physiological stressors, or biological systems [29], which suggests that a common reason for hormesis resides in some process shared by many organisms [30, 33]. A common explanation for hormesis is that the drug interacts with a homeostatic mechanism [30, 34]. Homeostasis refers to the maintenance of internal physiological conditions within ranges necessary for survival and reproduction [29, 30]. All organisms have homeostatic control mechanisms.

At least two important hypotheses attribute the effects of antidepressants on depressive symptoms to the adaptations produced by homeostatic mechanisms [14, 35, 36]. Hyman and Nestler argued that homeostatic adaptations to SSRIs are responsible for the antidepressant effect that often occurs over chronic treatment. “It is the adaptive response of the nervous system to adequate repeated perturbations mediated through these initial targets that produces the therapeutic responses to antidepressants...” [ref.

35, p. 152]. Thus, Hyman and Nestler focus on the changes that occur from the early (acute) phase of treatment to the chronic phase. Vetulani and Sulser similarly argued that adaptations in the noradrenergic system were responsible for the symptom-reducing effects of tricyclic antidepressants, monoamine oxidase inhibitors, and electroconvulsive therapy [36]. In contrast, Fava has argued that the loss of effectiveness during prolonged antidepressant use is caused by recruitment of “processes that oppose the initial acute effects of a drug...” [ref. 14, p. 127]. Moreover, oppositional forces may take time to dissipate after antidepressants are discontinued and the residual adaptations can result in the “appearance of withdrawal symptoms and increased vulnerability to relapse” [ibid]. Thus, Fava’s account also recognizes the multiphasic nature of the effects of antidepressants on depressive symptoms, focusing on the changes from chronic treatment to more prolonged treatment to discontinuation [37]. In principle, it is possible for both hypotheses to be correct because they refer to different phases of the hormetic response.

The CNS adapts to antidepressant exposure [35, 38–41], and these adaptations are sometimes referred to as *acquired tolerance* [23] or *oppositional tolerance* [14, 15]. However, the arguments of Hyman, Nestler, Vetulani, Sulser, and Fava require antidepressants to interact with a homeostatic mechanism. While Hyman, Nestler, Vetulani, and Sulser argue that the pertinent adaptations occur post-synaptically—in gene expression and receptor-mediated signaling pathways [35, 36]—it is not clear that gene expression or receptor signaling pathways are under direct homeostatic control. However, synaptic monoamine levels are under direct homeostatic control [38, 40], and nearly all effective antidepressants perturb synaptic monoamine concentrations [24]. Because synaptic serotonin is under homeostatic control, and SSRIs directly perturb synaptic serotonin through a common mechanism (reuptake blockade), it is plausible that SSRIs trigger oppositional adaptations that eventually restore synaptic serotonin to equilibrium conditions. These adaptations may be particularly good candidates for exploring the hormetic effects of SSRIs.

In this paper, we briefly discuss how hormetic responses can be produced from homeostatic control mechanisms before reviewing several serotonergic adaptations that oppose SSRIs and return synaptic serotonin to the homeostatic equilibrium: the inhibition of serotonin synthesis, the suppression of serotonergic neuron firing rates, and the inhibition of serotonin transmission (which is related to neuronal firing, but nevertheless distinct).

We then review the dissipation of oppositional tolerance after SSRI discontinuation. We also review how SSRIs may cause permanent adaptations in the serotonergic system.

Finally, we consider whether and how the adaptations to SSRIs that eventually restore synaptic serotonin to homeostatic equilibrium are related to the hormetic effects on depressive symptoms. Resolving this issue requires an understanding of the causal role of synaptic serotonin in depression. The conventional wisdom is that serotonin transmission is reduced in depression [42, 43]. The primary foundation for the *low serotonin hypothesis* is the fact that most antidepressants have the pharmaco-

logical property of rapidly increasing synaptic serotonin. However, the homeostatic mechanisms of the CNS produce adaptations that oppose the serotonin-elevating effects of antidepressants [38]. Thus, if adaptations are responsible for the alleviation of depressive symptoms, then it is conceivably possible that serotonin is elevated (rather than diminished) in depression—the *high serotonin hypothesis* [4]. Several empirical findings in rodents, primates, and humans have led some researchers to suggest that serotonin neurotransmission is elevated in depression [44–46]. Finally, some have questioned whether serotonin is causally involved in depression at all [47, 48].

Confusion over this issue can be reduced by being clear about our precise causal claim. If we could fully map out the neurological chain of events that trigger depression, we would probably find that some steps involve serotonin, while other neurotransmitters (e.g., norepinephrine, glutamate, GABA) are involved in other steps. Disabling the brain's ability to transmit serotonin to forebrain regions—by lesion, pharmacological inhibition, or *Tph2* gene knockout—prevents rodents from developing depression-like symptoms in rodent models of depression [49–52]. Serotonin is therefore a *necessary cause* for depression in these rodent models, but it is not a *sufficient cause* since there are also positive mood states in which serotonin neurotransmission is elevated [4]. Given an elevation in serotonin transmission, other neurological events must determine whether depression or some other state is induced. In inescapable shock, the transmission of serotonin to the rat's amygdala and striatum play crucial roles in the development of depressive symptoms, but it does this by affecting post-signaling receptor pathways involving the 5-HT_{2c} receptor [53]. Thus, serotonin transmission to the amygdala and striatum are more *distal causes* of depression in the inescapable shock model, while post-signaling receptor pathways within these regions are more *proximal causes* of depression. We will return to the precise causal role that serotonin plays in depression later in this paper. Finally, we reiterate the involvement of norepinephrine as another causal factor in affecting depressive symptoms [24], but we focus on adaptations to SSRIs in the serotonin system because they have been more widely studied. Even so, the principles of hormesis, homeostasis, and adaptation that we apply to SSRIs may also apply to antidepressants with noradrenergic properties.

Search strategy and selection criteria

We searched for relevant articles in PubMed and Google Scholar using “serotonin”, “adapt”, “adaptation”, “oppositional tolerance”, “acquired tolerance”, “hormesis”, “homeostasis”, “5-HIAA/5-HT”, “discontinuation”, “cessation”, “acute SSRI”, “chronic SSRI”, “fluoxetine”, and related terms. In the references of relevant articles, we sometimes found other relevant articles. We also searched articles that cited relevant articles.

Homeostasis and hormesis

A common way to produce hormetic responses is through the dynamical interplay between two opposing forces [26, 33, 34, 54]. The first force is the load that the drug puts on the system, which perturbs a physiological parameter from homeostatic equilibrium. This is the direct effect of the drug and it often produces the first part of the biphasic response. The second force is the negative feedback produced by the homeostatic mechanism to bring the parameter back into equilibrium. This negative feedback is responsible for the tolerance or adaptation to the drug [26, 55]. It often takes time for a homeostatic mechanism to build up oppositional tolerance, which is why there may be a delay in the control of the parameter.

The oppositional tolerance that accrues over the duration of drug exposure can cause a physiological parameter to overshoot or undershoot its equilibrium [55]. Over time, the parameter can show a dampened overshoot and undershoot oscillation pattern until it eventually re-equilibrates (Figure 1). The oscillation reflects the interplay between the load caused by the drug and fluctuating degrees of oppositional tolerance. The adaptive value of a control mechanism that responds to perturbations with a dampened oscillation pattern is that it brings the parameter back into equilibrium more rapidly, but it comes at some cost to stability [56].

Because synaptic serotonin is under homeostatic control [35, 38–41], oppositional tolerance to SSRIs could trigger a dampened oscillation in synaptic serotonin or other parameters that affect synaptic serotonin, and these might be related to the hormetic effects on depressive symptoms.




Figure 1. Hypothetical time course of a parameter (process variable) as it is disturbed from equilibrium (setpoint) by a drug, and as homeostatic control processes bring it back to equilibrium

Oppositional tolerance to restore synaptic homeostasis

If SSRIs are interacting with a system under homeostatic control, then the drugs should trigger responses in the CNS that return the system to equilibrium. The direct effect of SSRI molecules is to block serotonin transporter (SERT) sites, which prevents the reuptake of serotonin into the pre-synaptic neuron. SSRIs cause synaptic serotonin to significantly increase within minutes to hours after the first dose [7, 8]. Thus, if the total level of brain serotonin is the sum of the intracellular and extracellular (synaptic) pools, the direct effect of initial SSRI therapy must be to shift the allocations, increasing the extracellular pool of serotonin while reducing the intracellular pool (Figure 2).

The increase in synaptic serotonin concentration during initial SSRI treatment represents peak values, and extracellular serotonin levels gradually return to pre-SSRI values over time, despite continued administration (see, e.g., Figure 2 from [57] and Figure 2 from [58]). This return to premedication levels during chronic SSRI treat-




Figure 2. The effect of a single dose of an SSRI is to shift the relative allocation of intracellular and extracellular serotonin. With chronic SSRI treatment, extracellular serotonin concentrations eventually return to the premedication baseline. This effect is at least partly attributable to the inhibition of the synthesis of serotonin, which reduces the pool of intracellular serotonin available for neurotransmission and the total pool of serotonin in the brain

ment has been demonstrated in rats, mice and primates [57–59]. Several adaptations contribute to the return of synaptic serotonin to pre-SSRI levels.

Synthesis of serotonin

Numerous studies show that total serotonin content in brain regions decrease (rather than increase) during chronic antidepressant therapy [60–69]. Because extracellular serotonin does not go below the premedication equilibrium level during SSRI exposure, the decline in total brain serotonin content must be caused by a reduction in the intracellular serotonin pool (Figure 2). All classes of effective antidepressants inhibit the synthesis of serotonin, which reduces the intracellular pool of serotonin available for neurotransmission [62, 66, 70–72]. One study showed the dose-dependent inhibition of serotonin synthesis, with higher doses of fluoxetine causing greater inhibition [73].

Firing of serotonergic neurons

The inhibition of serotonin synthesis happens quickly after SSRI administration is initiated, but the effects accumulate slowly. SSRI administration also causes a rapid suppression of the firing rates of serotonergic neurons, which reduces the release of serotonin into the synapse [74]. The decrease in neuronal firing, however, is insufficient to bring synaptic serotonin concentrations back to premedication baseline. As noted above, extracellular serotonin levels decline slowly during chronic SSRI administration and serotonin concentrations only come back to pre-drug baseline after several weeks of treatment. This occurs because SSRI doses are usually upward titrated to occupy 70–80% of available SERT sites [39, 75]. The brain cannot fully compensate for this by decreasing neuronal firing rates, which is why it takes several weeks for synaptic serotonin concentrations to return to pre-drug levels. Without suppression of neuronal firing, however, synaptic serotonin would be even more perturbed from equilibrium. Over several weeks—as the inhibition of serotonin synthesis gradually causes synaptic serotonin to return to normal—serotonergic neurons also return slowly to their normal firing rates [74].

Serotonin transmission

Elsewhere, we have reviewed evidence that the ratio of the concentrations of 5-hydroxyindoleacetic acid (5-HIAA) to serotonin (5-HT) is a useful surrogate index for measuring regional serotonin neurotransmission, although sometimes 5-HIAA concentrations by themselves are used for this purpose [4]. One study involving primates [57] reported a reduced 5-HIAA/5-HT ratio in multiple brain regions during chronic fluoxetine treatment (Figure 3). Moreover, there appears to be a dampened oscillation in the 5-HIAA/5-HT ratio around the lower equilibrium (Figure 3). The inhibition of transmission appears to be quite rapid since another study involving mice reported




Figure 3. **The 5-HIAA/5-HT ratio in three regions (caudate, hippocampus, neocortex) is reduced following the initiation of fluoxetine treatment and remains reduced for the duration of treatment. The ratio seems to show a dampened oscillation around the new, lower equilibrium [data are from ref. 59]**

a decrease in the 5-HIAA/5-HT ratio after a single injection of fluoxetine [73]. Another study involving humans showed that chronic SSRI use reduced 5-HIAA levels in the jugular vein, which directly drains the brain with little peripheral contamination [44].

The effects of SSRIs on firing rates of serotonin neurons (i.e., initial suppression, followed by return to baseline) and on neurotransmission (i.e., continued suppression indexed by the 5-HIAA/5-HT ratio) may appear paradoxical. Should not the return of serotonin neuronal firing rates to normal also result in a return of transmission to normal? These two observations can be reconciled by the fact that synthesis is suppressed during treatment as well. The return of neuronal firing rates to normal will not increase transmission if there is less serotonin available for transmission.

Dissipation of oppositional tolerance after discontinuation

After SSRI discontinuation, the load on the system caused by the drug is relaxed, and oppositional tolerance should gradually dissipate. Thus, we predict changes to brain serotonin content, neuronal firing, and neurotransmission after drug discontinuation (Table 1). For instance, shortly after discontinuation when the drug has been effectively cleared from the system, there should be a shift in the allocation of the brain's serotonin where the intracellular pool of serotonin increases and the extracellular pool decreases. This should cause synaptic serotonin to fall below equilibrium and

trigger adaptations to restore equilibrium (increase in serotonergic neuron firing rate, increase in synthesis, increase in 5-HIAA/5-HT). During the chronic discontinuation phase, these adaptations will eventually restore overall serotonin content in the brain to premedication levels. As the discontinuation period becomes more prolonged, the system should eventually return to premedication conditions.

Few studies have examined what happens to the serotonin system after SSRI discontinuation, but two are relevant. In the first study, mice were injected with fluoxetine for three weeks and then followed for up to 17 days after discontinuing treatment [73]. After discontinuation, the synthesis of serotonin and the 5-HIAA/5-HT ratio exhibited a dampened oscillation pattern in three regions—hypothalamus, hippocampus, and frontal cortex. Specifically, there was an overshoot that peaked at day 3, followed by a gradual return to pre-fluoxetine values by day 17.

In the second study (discussed in more detail in the Supplement), rats were treated with fluoxetine for three weeks [76]. The drug was then discontinued, and the rats were followed for varying periods of time before they were sacrificed to measure serotonin and 5-HIAA concentrations in four brain regions—hippocampus, cortex, hypothalamus, and pons medulla (Supplement, Figures S1 and S2). During fluoxetine treatment, there was a loss in the total serotonin content of the brain and a reduction in the 5-HIAA/5-HT ratio, consistent with the patterns noted above. After discontinuation, total brain serotonin content gradually returned to premedication levels. Also, the 5-HIAA/5-HT ratio exhibited an overshoot several days after discontinuation before returning to premedication levels.

These two studies suggest that, after SSRI discontinuation: (1) the oppositional tolerance that accumulated during chronic SSRI administration gradually dissipates until synaptic serotonin levels return to premedication equilibrium; and (2) as oppositional tolerance dissipates, the system exhibits a dampened oscillation in serotonin synthesis and 5-HIAA/5-HT ratio until it re-equilibrates.

SSRIs can permanently alter the serotonin system

The CNS sometimes responds to synaptic perturbations by making adjustments of a relatively permanent nature that restore equilibrium. This can happen, for instance, when organisms are exposed to psychotropic drugs during early development. Neonatal SSRI exposure can cause changes to the components of the serotonin system involved in synthesis and reuptake—Tph2 and SERT expression—that persist into adulthood [77–80]. The precise directional changes depend on other factors (e.g., the specific SSRI used), but these studies demonstrate the principle that exposure to SSRIs can induce permanent changes to the serotonin system.

Discussion

From a hormetic perspective, the worsening of symptoms that sometimes occurs during early SSRI treatment represents an overshoot relative to the premedication symptom level, while the therapeutic effect that develops during chronic SSRI treatment represents an undershoot. Tachyphylaxis over more prolonged treatment arguably represents a return of depressive symptoms to premedication levels, and it is possible that relapses after SSRI discontinuation may be overshoots. For instance, the risk of relapse after the discontinuation of effective cognitive behavioral therapy (CBT) is lower than the risk of relapse after the discontinuation of effective SSRI treatment [25].

The literature on hormesis suggests that this pattern could be caused by the SSRI interacting with one or more homeostatic control mechanisms. Synaptic serotonin is under homeostatic control, and we have reviewed several adaptations to SSRIs in the serotonin system that return synaptic serotonin to the premedication equilibrium.

Do these adaptations contribute to the hormetic effects of SSRIs on depressive symptoms? An answer to this question requires an assumption about the direction of association between serotonin and depression.

Serotonin and depression

The low serotonin hypothesis of depression originated with the discovery that certain drugs with antidepressant effects had the property of acutely increasing synaptic norepinephrine or serotonin [5, 6]. However, the therapeutic delay between treatment initiation and clinical response has long been recognized as problematic for the low serotonin hypothesis [10].

Nevertheless, researchers have attempted to explain the therapeutic delay by working within the low serotonin framework. One attempt relied upon the fact that the firing of serotonergic neurons is suppressed during acute treatment by activation of the 5-HT_{1A} autoreceptor, which is inhibitory. During chronic treatment, however, the autoreceptor becomes desensitized and firing rates return to normal [35, 74]. The suppression of neuronal firing that occurs with acute SSRI treatment should decrease neurotransmission to forebrain regions, which could possibly reconcile the therapeutic delay with the low serotonin hypothesis. The problem with the autoreceptor desensitization hypothesis is that synaptic serotonin increases rapidly after a single SSRI dose [7, 8]. Thus, irrespective of firing rates, SERT blockade is effective in increasing synaptic serotonin concentrations, and the low serotonin hypothesis predicts this should cause a rapid alleviation in symptoms, which it does not do.

The widespread acceptance of the low serotonin hypothesis is surprising because rodent models of depression have provided substantial evidence that contradicts it. Inescapable shock—perhaps the most widely studied rodent model of depression—increases extracellular serotonin concentrations in the prefrontal cortex, striatum, amygdala, periaqueductal gray, and other forebrain regions [49, 81]. Indeed, most studies of rodent models of depression have found elevated extracellular serotonin, 5-HIAA, or

the 5-HIAA/5-HT ratio in a number of forebrain regions [4]. Other researchers have also noticed how the direct measurements contradict the low serotonin hypothesis [44–46] (see also Supplement, Table S1).

More evidence against the low serotonin hypothesis comes from studies that disable the rodent brain's ability to transmit serotonin to forebrain regions via surgical lesioning, pharmacological inhibition, or *Tph2* gene knockout [49–52]. According to the low serotonin hypothesis, these manipulations should all induce depressive-like symptoms in rodents. In fact, they do not [4]. Instead, they prevent the rodent from developing depressive symptoms in response to otherwise depressogenic stressors (e.g., inescapable shock, chronic social defeat, chronic mild stress) [49–52]. In their review of 50 years of research on inescapable shock, Steve Maier and Martin Seligman review evidence that elevated serotonin transmission—particularly to the striatum and amygdala—is “necessary and sufficient” to produce the depressive symptoms uniquely triggered by inescapable shock [ref. 50, p. 352].

It could be argued that rodents are not good models for understanding human depression. However, inescapable shock produces most symptoms of depression, including some of the cognitive effects [49]. Moreover, the mammalian brain is highly conserved, and rodent models are extensively used in understanding the neurobiology of many depression-related phenomena, such as the reduction in hippocampal neurogenesis and the effects of antidepressants. It makes little sense to argue that rodents are not a good model for depression without also giving up everything we have learned from those models. Given the influential impact of the inescapable shock paradigm on the understanding of depression, it is puzzling how the effect of inescapable shock on serotonin has gone largely unnoticed by psychiatric and pharmacological researchers.

In humans, research on the relationship between serotonin and depression is hindered by the inability to directly measure serotonin in the brain without invasive techniques [4]. Nevertheless, two well-designed studies suggest that serotonin transmission is elevated in unmedicated people with clinically diagnosed depression.

One neuroimaging study examined SERT expression in 20 depressed patients and 10 healthy volunteers who were either medication-naïve or medication-free for at least one year using a single photon emission computed tomography radioligand highly specific for SERT [82]. The depressed patients had lower levels of SERT in the midbrain, basal ganglia and temporal lobe. Moreover, responders to the non-pharmacologic intervention of CBT, versus non-response to CBT, showed a significant increase in SERT expression [83]. Because SERT clears serotonin from the synapse, these results are consistent with an increase in synaptic serotonin in depressed patients, and a decrease in synaptic serotonin with effective treatment.

While brain 5-HIAA levels can serve as a good proxy for serotonin transmission, 5-HIAA levels in the spinal fluid of human lumbar region are contaminated by peripheral sources [44]. To avoid this problem, another well-designed study examined brain 5-HIAA overflow in the jugular vein of humans, which comes from the brain with little peripheral contamination [44]. Investigators studied 21 depressed subjects, nearly all of

whom had been medication-free for at least one year, and 40 non-depressed controls. Relative to non-depressed controls, there was a higher overflow of 5-HIAA in the jugular veins of the depressed subjects. Moreover, 5-HIAA concentrations decreased over 12 weeks of SSRI therapy. This finding corroborates the evidence in non-human animals (discussed above) that SSRIs suppress serotonin neurotransmission (indexed by 5-HIAA or 5-HIAA/5-HT).

Some studies have attempted to test the low serotonin hypothesis in humans by providing participants with a drink that is depleted of tryptophan in an attempt to reduce the availability of brain serotonin. These studies have failed to trigger depressive symptoms in otherwise healthy people [84]. However, tryptophan depletion triggers depressive symptoms in remitted patients who have currently or previously used serotonergic antidepressants [84]. In such patients, it does not suppress DRN activity, as the low serotonin hypothesis predicts. Rather, it activates the DRN [85], which is consistent with the high serotonin hypothesis. This finding could be explained by the downregulation of the 5-HT_{1A} autoreceptor during acute tryptophan depletion, which may be a compensatory homeostatic response that disinhibits the DRN [86].

Altogether, these findings suggest that serotonin neurotransmission to certain forebrain regions is elevated in depression, and it may be necessary to the development of depressive symptoms.

How the serotonin system may contribute to the hormetic effects of SSRIs

In attempting to explain how serotonergic adaptations contribute to the hormetic effects of SSRIs, we therefore start with the assumption that serotonin transmission is elevated in depression, at least to forebrain regions like the striatum and basolateral amygdala.

Early worsening of symptoms

Although chronic SSRI treatment commonly reduces depressive symptoms, a worsening of symptoms is sometimes observed shortly after treatment is initiated [12, 13]. Perhaps the most potent demonstration of this is the increased risk of suicidal thoughts and behavior in the first few days after initiating antidepressant treatment [87]. The high serotonin hypothesis for depression provides a natural explanation for the early worsening of symptoms, because the earliest pharmacological effect of SSRIs is to increase synaptic serotonin even further.

The reason why many patients do not experience early worsening is unknown. Early worsening of anxiety or depression is sometimes studied experimentally with single-dose or sub-chronic SSRI treatments [88]. In both rodents and humans, a single dose of SSRIs increases the symptoms of anxiety [89, 90] and potentiates fear responses [91–93]. Two studies of human volunteers suggest that SSRIs may potentiate anhedonia during early treatment. In one, a sub-chronic dose of citalopram reduced

the neural response to chocolate in areas involved in reward [94]. In the other, a single dose of paroxetine reduced the neural signal involved in motivation for a monetary reward [88]. Similarly, single doses of SSRIs often decrease reward-related activity in rodents [95–97]. However, these studies usually involve non-depressed individuals, which raises the issue of whether SSRIs worsen symptoms in depressed patients. Anecdotally, the worsening of symptoms during early antidepressant treatment may be more likely when the symptoms are mild [88]. It is possible that potential ceiling effects limit early worsening in patients with more severe symptoms.

There is interesting experimental evidence suggesting that early worsening may be less likely to occur in patients with more severe symptoms. In non-depressed human controls and in non-stressed rodents, a single dose of an SSRI increases the activation of the hypothalamus-pituitary-adrenal (HPA) axis [98–104]. However, in stressed animals and depressed patients, single SSRI doses do not affect HPA activity [103, 105]. Since the HPA axis is often hyperactivated in depression, a single dose of an SSRI appears to have little effect on an already activated stress response, which is consistent with a ceiling effect. Of course, the HPA activity of depressed patients is reduced by chronic SSRI treatment [106].

The therapeutic delay

The therapeutic delay is also naturally explained by the high serotonin hypothesis in a way that is consistent with the adaptation framework that Hyman and Nestler espouse. Since SSRIs increase synaptic serotonin even further, one must resort to the gradual development of adaptations that oppose this elevation to explain the delayed therapeutic effect. The evidence that serotonin is necessary for the development of depressive symptoms suggests that the antidepressant effect could be linked to the gradual loss of serotonin content in the brain.

Limited effectiveness

The symptom reducing effect of antidepressants during chronic treatment—relative to placebo—is not large [107–109]. This is also potentially explainable by the framework we suggest. Specifically, the oppositional tolerance that develops should be proportional to the strength of the drug [24]. In other words, a drug that is more effective in perturbing synaptic serotonin should trigger a stronger oppositional tolerance [24]. The fact that drug and the oppositional tolerance tend to cancel each other out could explain the limited effectiveness of antidepressants.

Tachyphylaxis

Over sufficiently long time periods, the CNS should fully equilibrate to the load imposed by SSRIs, so the return of depressive symptoms over the course of prolonged

SSRI use (tachyphylaxis) is somewhat to be expected [14]. However, it is difficult to explain tachyphylaxis solely in terms of adaptations in the serotonin system. For instance, if the loss of serotonin content is a sufficient, proximal cause of the antidepressant effect, then one might expect that tachyphylaxis would involve the return of serotonin content to premedication levels. However, the serotonin content of the brain remains depleted during prolonged SSRI use; it only returns to premedication levels sometime after discontinuation (Supplement, Figures S1 and S2). Somehow, the return of depressive symptoms must occur despite the loss of serotonin content. In this context, we note that total serotonin content is only reduced with chronic SSRI administration—it is not eliminated. It may be that adaptations in other neurotransmitter systems allow the brain to use what serotonin is available to bring about tachyphylaxis.

Again, we suggest that the transmission of serotonin to specific forebrain regions—such as the striatum and amygdala—is a necessary, somewhat distal cause of depression. In these regions, activity in post-synaptic neurons plays a more proximal role. Moreover, proper synaptic function requires maintaining the ratio of excitation and inhibition at a homeostatic equilibrium [110], which is modulated by both serotonin and dopamine [111]. By provoking adaptations in the serotonin system, it is possible that SSRIs may indirectly trigger dampened oscillations in neuronal activity in relevant forebrain regions that account for the hormetic overshoots and undershoots in depressive symptoms during SSRI therapy, as well as tachyphylaxis. Again, adaptations in other neurotransmitter systems may contribute to the hormetic effects in depressive symptoms.

Relapse after discontinuation

Upon SSRI discontinuation, the load caused by the drug is removed, and the oppositional tolerance that has accumulated causes the system to dis-equilibrate. As extracellular serotonin falls below equilibrium, there could be a reduction in depressive symptoms, which is a prediction that we believe has never been tested. Moreover, we suggest that the relapse that often occurs after discontinuation [14, 24, 25, 37] represents an overshoot caused by the increase in serotonin content and transmission during this period. This overshoot mirrors the undershoot in depressive symptoms that occurs during chronic SSRI treatment. As the period of discontinuation becomes more prolonged, the system should eventually return to premedication conditions.

Stepwise Resistance

Hyman and Nestler suggested that the adaptations induced by SSRIs can lock the system into a therapeutic state that outlasts the duration of drug treatment [35]. This suggestion is supported by the research discussed above in which neonatal SSRI exposure produces changes in the CNS that persist into adulthood. Unfortunately, the alterations to the system are often not therapeutic in the way that Hyman and Nestler

hoped. Many of the studies show that rats exposed as neonates develop a depressed or anxious symptom profile when they reach adulthood [78, 112].

The phenomenon of stepwise resistance—where there is a loss of treatment effectiveness over repeated antidepressant treatment trials [18–23, 113–115]—suggests that exposure to SSRIs and other antidepressants can permanently alter the CNS even in adulthood. This is a within-person effect; it cannot be explained by stable between-person differences. Moreover, stepwise resistance does not appear to be caused by new episodes that happen shortly after discontinuation when oppositional tolerance has not fully dissipated, as this phenomenon can occur years after previous episodes have resolved.

Mechanistically, it is not clear how stepwise resistance in adults is achieved. One possibility comes from evidence that chronic fluoxetine administration in adult rats can induce hippocampal and prefrontal cortex neurons into a less mature state [116, 117]. The neuroplasticity seen in de-matured rat neurons is similar to that seen during critical developmental stages [118, 119], which suggests that adult SSRI exposure in humans can push neurotransmitter systems into a sensitive developmental stage where they may be permanently altered by the drugs.

Conclusion

Hyman and Nestler [35] argued that adaptations to SSRIs explain the therapeutic delay, while Fava [14] argued that adaptations to SSRIs explain tachyphylaxis and the increased risk of relapse after discontinuation. The concepts of hormesis and homeostasis can provide a unifying framework for understanding how both proposals may be correct. When interacting with a drug that perturbs a system from equilibrium, a homeostatic control mechanism often causes the system to alternate between positive and negative responses until it eventually equilibrates to the drug. SSRIs disrupt synaptic serotonin from its homeostatic equilibrium, and we have reviewed several adaptations in the serotonin system that may contribute to the hormetic effects of SSRIs. A complete understanding of how SSRIs affect depressive symptoms will require a full exploration of their temporally dynamic effects on multiple neurotransmitter systems.

Author contributions: PWA and JDA both contributed to the conceptual design and the writing of the paper. Additionally, they both approved the final draft and are accountable for all aspects of the work.

Conflicts of interests: None declared.

Funding: This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Acknowledgments: We thank Steve Maier for comments on the manuscript.

References

1. Schildkraut JJ. *The catecholamine hypothesis of affective disorders: A review of supporting evidence*. Am. J. Psychiatry 1965; 122(5): 509–522.
2. Coppen A. *The biochemistry of affective disorders*. Br. J. Psychiatry 1967; 113(504): 1237–1264.
3. Lapin IP, Oxenkrug GF. *Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect*. Lancet 1969; 293(7586): 132–136.
4. Andrews PW, Bharwani A, Lee KR, Fox M, Thomson JA Jr. *Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response*. Neurosci. Biobehav. Rev. 2015; 51: 164–188.
5. Krishnan V, Nestler EJ. *The molecular neurobiology of depression*. Nature 2008; 455(7215): 894–902.
6. Belmaker RH, Agam G. *Major depressive disorder*. N. Engl. J. Med. 2008; 358(1): 55–68.
7. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L et al. *Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex*. Psychopharmacology 2002; 160(4): 353–361.
8. Rutter JJ, Auerbach SB. *Acute uptake inhibition increases extracellular serotonin in the rat forebrain*. J. Pharmacol. Exp Ther. 1993; 265(3): 1319–1324.
9. Charney DS, Menkes DB, Heninger GR. *Receptor sensitivity and the mechanism of action of antidepressant treatment: Implications for the etiology and therapy of depression*. Arch. Gen. Psychiatry 1981; 38(10): 1160–1180.
10. Oswald I, Brezinova V, Dunleavy DLF. *On the slowness of action of tricyclic antidepressant drugs*. Br. J. Psychiatry 1972; 120(559):673–677.
11. Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley JC et al. *Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: Prevalence and implications*. J. Clin. Psychiatry 2007; 68(1): 52–57.
12. Haslam C, Brown S, Atkinson S, Haslam R. *Patients' experiences of medication for anxiety and depression: Effects on working life*. Fam. Pract. 2004; 21(2): 204–212.
13. Porter RS, Kaplan JL, editors. *The Merck Manual of Diagnosis and Therapy*, 19th Edition. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2011.
14. Fava GA. *Can long-term treatment with antidepressant drugs worsen the course of depression?* J. Clin. Psychiatry 2003; 64(2): 123–133.
15. Fava GA, Offidani E. *The mechanisms of tolerance in antidepressant action*. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011; 35(7): 1593–1602.
16. Byrne SE, Rothschild AJ. *Loss of antidepressant efficacy during maintenance therapy: Possible mechanisms and treatments*. J. Clin. Psychiatry 1998; 59(6): 279–288.
17. Kinrys G, Gold AK, Pisano VD, Freeman MP, Papakostas GI, Mischoulon D et al. *Tachyphylaxis in major depressive disorder: A review of the current state of research*. J. Affect. Disord. 2019; 245: 488–497.
18. Amsterdam JD, Williams D, Michelson D, Adler LA, Dunner DL, Nierenberg AA et al. *Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder*. Neuropsychobiology 2009; 59(4): 227–233.
19. Amsterdam JD, Maislin G, Potter L. *Fluoxetine efficacy in treatment resistant depression*. Prog. Neuropsychopharmacol. Biol. Psychiatry 1994; 18(2): 243–261.

20. Hsu JH, Mulsant BH, Lenze EJ, Karp JF, Lavretsky H, Roose SP et al. *Impact of prior treatment on remission of late-life depression with venlafaxine and subsequent aripiprazole or placebo augmentation.* American J. Geriatr. Psychiatry 2016; 24(10): 918–922.
21. Hunter AM, Cook IA, Tartter M, Sharma SK, Disse GD, Leuchter AF. *Antidepressant treatment history and drug-placebo separation in a placebo-controlled trial in major depressive disorder.* Psychopharmacology 2015; 232(20): 3833–3840.
22. Kim T, Xu C, Amsterdam JD. *Relative effectiveness of tricyclic antidepressant versus monoamine oxidase inhibitor monotherapy for treatment-resistant depression.* J. Affect. Disord. 2019; 250: 199–203.
23. Leykin Y, Amsterdam JD, DeRubeis RJ, Gallop R, Shelton RC, Hollon SD. *Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression.* J. Consult. Clin. Psychol. 2007; 75(2): 267–276.
24. Andrews PW, Kornstein S, Halberstadt L, Gardner C, Neale MC. *Blue again: Perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression.* Front. Psychol. 2011; 2: 159.
25. Cuijpers P, Hollon SD, Straten A van, Bockting C, Berking M, Andersson G. *Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis.* BMJ Open 2013; 3(4): e002542.
26. Stebbing ARD. *Adaptive responses account for the β -curve—hormesis is linked to acquired tolerance.* Nonlinearity Biol. Toxicol. Med. 2003;1(4): 493–511.
27. Calabrese EJ, Baldwin LA. *Toxicology rethinks its central belief.* Nature 2003; 421: 691–692.
28. Calabrese EJ, Baldwin LA. *The hormetic dose-response model is more common than the threshold model in toxicology.* Toxicol. Sci. 2003; 71(2): 246–50.
29. Mattson MP, Calabrese EJ, editors. *Hormesis: A revolution in biology, toxicology and medicine.* New York: Springer; 2010.
30. Stebbing ARD. *Hormesis — The stimulation of growth by low levels of inhibitors.* Sci. Total Environ. 1982; 22(3): 213–234.
31. Calabrese EJ, Baldwin LA. *Hormesis: U-shaped dose responses and their centrality in toxicology.* Trends Pharmacol. Sci. 2001; 22(6): 285–291.
32. Calabrese EJ, Baldwin LA. *The frequency of U-shaped dose responses in the toxicological literature.* Toxicol. Sci. 2001; 62(2): 330–338.
33. Calabrese EJ. *Overcompensation stimulation: A mechanism for hormetic effects.* Crit. Rev. Toxicol. 2001; 31(4–5): 425–470.
34. Stebbing ARD. *Interpreting ‘dose-response’ curves using homeodynamic data: with an improved explanation for hormesis.* Dose-Response 2009; 7(3): 221–233.
35. Hyman SE, Nestler EJ. *Initiation and adaptation: A paradigm for understanding psychotropic drug action.* Am. J. Psychiatry 1996; 153(2): 151–162.
36. Vetulani J, Sulser F. *Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain.* Nature 1975; 257(5526): 495–496.
37. Fava GA, Cosci F. *Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs.* J. Clin. Psychiatry 2019; 80(6): 19com12794
38. Best J, Nijhout HF, Reed M. *Serotonin synthesis, release and reuptake in terminals: A mathematical model.* Theor. Biol. Med. Model. 2010; 7(1): 34.
39. Blier P. *Resiliency of monoaminergic systems: The 80% rule and its relevance to drug development.* J. Psychopharmacol. 2008; 22(6): 587–589.

40. Stricker EM, Zigmond MJ. *Brain monoamines, homeostasis, and adaptive behavior: handbook of physiology: Intrinsic regulatory systems of the brain*. Bethesda, MD: American Physiological Society; 1986. P. 677–700.
41. Young AM, Goudie AJ. *Adaptive processes regulating tolerance to behavioral effects of drugs*. In: Bloom FE, Kupfer DJ, editors. *Psychopharmacology: The fourth generation of progress*. New York: Raven Press; 1995. P. 733–742.
42. Albert PR, Benkelfat C, Descarries L. *The neurobiology of depression—Revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms*. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2012; 367(1601): 2378–2381.
43. Maes M, Meltzer HY. *The serotonin hypothesis of major depression*. In: Bloom FE, Kupfer DJ, editors. *Psychopharmacology: The fourth generation of progress*. New York: Raven Press; 1995. P. 921–932.
44. Barton DA, Esler MD, Dawood T, Lambert EA, Haikerwal D, Brenchley C et al. *Elevated brain serotonin turnover in patients with depression: Effect of genotype and therapy*. Arch. Gen. Psychiatry 2008; 65(1): 38–46.
45. Petty F, Kramer G, Wilson L, Jordan S. *In vivo serotonin release and learned helplessness*. Psychiatry Res. 1994; 52(3): 285–293.
46. Zangen A, Overstreet DH, Yadid G. *High serotonin and 5-hydroxyindoleacetic acid levels in limbic brain regions in a rat model of depression; Normalization by chronic antidepressant treatment*. J. Neurochem. 1997; 69(6) :2477–2483.
47. Kirsch I. *The emperor's new drugs: Exploding the antidepressant myth*. New York, NY: Basic Books; 2010.
48. Lacasse JR, Leo J. *Serotonin and depression: A disconnect between the advertisements and the scientific literature*. PLoS Medicine 2005; 2(12): e392.
49. Maier SF, Seligman MEP. *Learned helplessness at fifty: Insights from neuroscience*. Psychol. Rev. 2016; 123(4): 349–367.
50. Chung KKK, Martinez M, Herbert J. *Central serotonin depletion modulates the behavioural, endocrine and physiological responses to repeated social stress and subsequent c-fos expression in the brains of male rats*. Neuroscience 1999; 92(2): 613–625.
51. Yalcin I, Coubard S, Bodard S, Chalon S, Belzung C. *Effects of 5,7-dihydroxytryptamine lesion of the dorsal raphe nucleus on the antidepressant-like action of tramadol in the unpredictable chronic mild stress in mice*. Psychopharmacology 2008; 200(4): 497–507.
52. Angoa-Pérez M, Kane MJ, Briggs DI, Herrera-Mundo N, Sykes CE, Francescutti DM et al. *Mice genetically depleted of brain serotonin do not display a depression-like behavioral phenotype*. ACS Chem. Neurosci. 2014; 5(10): 908–919.
53. Amat J, Baratta MV, Paul E, Bland ST, Watkins LR, Maier SF. *Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus*. Nat. Neurosci. 2005; 8(3): 365–371.
54. Calabrese EJ. *Hormesis within a mechanistic context*. Homeopathy 2015; 104(2): 90–96.
55. Stebbing ARD. *Hormesis: Interpreting the β -curve using control theory*. J. Appl. Toxicol. 2000; 20(2): 93–101.
56. O'Leary T, Wyllie DJA. *Neuronal homeostasis: Time for a change?* J. Physiol. 2011; 589(20): 4811–4826.
57. Smith TD, Kuczenski R, George-Friedman K, Malley JD, Foote SL. *In vivo microdialysis assessment of extracellular serotonin and dopamine levels in awake monkeys during sustained fluoxetine administration*. Synapse 2000; 38(4): 460–470.

58. Popa D, Cerdan J, Repérant C, Guiard BP, Guilloux J-P, David DJ et al. *A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain.* Eur. J. Pharmacol. 2010; 628(1): 83–90.
59. Malagie I, Deslandes A, Gardier AM. *Effects of acute and chronic tianeptine administration on serotonin outflow in rats: Comparison with paroxetine by using in vivo microdialysis.* Eur. J. Pharmacol. 2000; 403(1): 55–65.
60. Adell A, García-Marquez C, Armario A, Gelpí E. *Chronic administration of clomipramine prevents the increase in serotonin and noradrenaline induced by chronic stress.* Psychopharmacology 1989; 99(1): 22–26.
61. Alpers HS, Himwich HE. *The effects of chronic imipramine administration on rat brain levels of serotonin, 5-hydroxyindoleacetic acid, norepinephrine and dopamine.* J. Pharmacol. Exp. Ther. 1972; 180(3): 531–538.
62. Bosker FJ, Tanke MAC, Jongsma ME, Cremers TIFH, Jagtman E, Pietersen CY et al. *Biochemical and behavioral effects of long-term citalopram administration and discontinuation in rats: Role of serotonin synthesis.* Neurochem. Int. 2010; 57(8): 948–957.
63. Caccia S, Anelli M, Codegoni AM, Fracasso C, Garattini S. *The effects of single and repeated anorectic doses of 5-hydroxytryptamine uptake inhibitors on indole levels in rat brain.* Br. J. Pharmacol. 1993; 110(1): 355–359.
64. Caccia S, Fracasso C, Garattini S, Guiso G, Sarati S. *Effects of short – and long-term administration of fluoxetine on the monoamine content of rat brain.* Neuropharmacology 1992; 31(4): 343–347.
65. Carruba MO, Picotti GB, Zambotti F, Mantegazza P. *Effects of mazindol, fenfluramine and chlorimipramine on the 5-hydroxytryptamine uptake and storage mechanisms in rat brain: Similarities and differences.* NaunynSchmiedeberg Arch. Pharmacol. 1977; 300(3): 227–232.
66. Honig G, Jongsma ME, Hart MCG van der, Tecott LH. *Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain.* PLoS ONE 2009; 4(8): e6797.
67. Hrdina PD. *Regulation of high – and low-affinity [3H]imipramine recognition sites in rat brain by chronic treatment with antidepressants.* Eur. J. Pharmacol. 1987; 138(2): 159–168.
68. Marsteller DA, Barbarich-Marsteller NC, Patel VD, Dewey SL. *Brain metabolic changes following 4-week citalopram infusion: Increased 18FDG uptake and γ -amino butyric acid levels.* Synapse 2007; 61(11): 877–881.
69. Ross SB, Hall H, Renyi AL, Westerlund D. *Effects of zimelidine on serotonergic and noradrenergic neurons after repeated administration in the rat.* Psychopharmacology 1981; 72(3): 219–225.
70. Carlsson A, Lindqvist M. *Effects of antidepressant agents on the synthesis of brain monoamines.* J. Neural. Transm. 1978; 43(2): 73–91.
71. Moret C, Briley M. *Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain.* Eur. J. Pharmacol. 1996; 295(2): 189–197.
72. Moret C, Briley M. *Effect of antidepressant drugs on monoamine synthesis in brain in vivo.* Neuropharmacology 1992; 31(7): 679–684.
73. Stenfors C, Ross SB. *Evidence for involvement of 5-hydroxytryptamine_{1B} autoreceptors in the enhancement of serotonin turnover in the mouse brain following repeated treatment with fluoxetine.* Life Sci. 2002; 71(24): 2867–2880.
74. Blier P, de Montigny C. *Current advances and trends in the treatment of depression.* Trends Pharmacol. Sci. 1994; 15(7): 220–226.

75. Preskorn SH. *Clinical pharmacology of selective serotonin reuptake inhibitors*. Caddo, OK: Professional Communications; 1996.
76. Trouvin JH, Gardier AM, Chanut E, Pages N, Jacquot C. *Time course of brain serotonin metabolism after cessation of long-term fluoxetine treatment in the rat*. *Life Sci*. 1993; 52(18): PL187–192.
77. Altieri SC, Yang H, O'Brien HJ, Redwine HM, Senturk D, Hensler JG et al. *Perinatal vs genetic programming of serotonin states associated with anxiety*. *Neuropsychopharmacology* 2015; 40(6): 1456–1470.
78. Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RCS et al. *Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry*. *Neuropsychopharmacology* 2006; 31(1): 47–57.
79. Simpson KL, Weaver KJ, Villers-Sidani E de, Lu JY-F, Cai Z, Pang Y et al. *Perinatal antidepressant exposure alters cortical network function in rodents*. *PNAS* 2011; 108(45): 18465–18470.
80. Weaver KJ, Paul IA, Lin RCS, Simpson KL. *Neonatal exposure to citalopram selectively alters the expression of the serotonin transporter in the hippocampus: Dose-dependent effects*. *Anat. Rec.* 2010; 293(11): 1920–1932.
81. Maier SF, Watkins LR. *Stressor controllability and learned helplessness: The roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor*. *Neurosci. Biobehav. Rev.* 2005; 29(4): 829–841.
82. Newberg AB, Amsterdam JD, Wintering N, Shults J. *Low brain serotonin transporter binding in major depressive disorder*. *Psychiatry Res. Neuroimaging* 2012; 202(2): 161–167.
83. Amsterdam JD, Newberg AB, Newman CF, Shults J, Wintering N, Soeller I. *Change over time in brain serotonin transporter binding in major depression: Effects of therapy measured with [123I]-ADAM SPECT*. *J. Neuroimaging* 2013; 23(4): 469–476.
84. Ruhé HG, Mason NS, Schene AH. *Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: A meta-analysis of monoamine depletion studies*. *Mol. Psychiatry* 2007; 12(4): 331–359.
85. Morris JS, Smith KA, Cowen PJ, Friston KJ, Dolan RJ. *Covariation of activity in habenula and dorsal raphé nuclei following tryptophan depletion*. *Neuroimage* 1999; 10(2): 163–172.
86. Cahir M, Ardis T, Reynolds GP, Cooper SJ. *Acute and chronic tryptophan depletion differentially regulate central 5-HT1A and 5-HT2A receptor binding in the rat*. *Psychopharmacology* 2007; 190(4): 497–506.
87. Jick H, Kaye JA, Jick SS. *Antidepressants and the risk of suicidal behaviors*. *JAMA* 2004; 292(3): 338–343.
88. Marutani T, Yahata N, Ikeda Y, Ito T, Yamamoto M, Matsuura M et al. *Functional magnetic resonance imaging study on the effects of acute single administration of paroxetine on motivation-related brain activity*. *Psychiatry Clin. Neurosci.* 2011; 65(2): 191–198.
89. Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S. *Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635*. *Int. J. Neuropsychopharmacol.* 2001; 4(4): 399–408.
90. Grillon C, Levenson J, Pine DS. *A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: A fear-potentiated startle study*. *Neuropsychopharmacology* 2007; 32(1): 225–231.
91. Burghardt NS, Bauer EP. *Acute and chronic effects of selective serotonin reuptake inhibitor treatment on fear conditioning: Implications for underlying fear circuits*. *Neuroscience* 2013; 247: 253–272.

92. Bigos KL, Pollock BG, Aizenstein HJ, Fisher PM, Bies RR, Hariri AR. *Acute 5-HT reuptake blockade potentiates human amygdala reactivity*. *Neuropsychopharmacology* 2008; 33(13): 3221–3225.
93. Murphy SE, Norbury R, O’Sullivan U, Cowen PJ, Harmer CJ. *Effect of a single dose of citalopram on amygdala response to emotional faces*. *Br. J. Psychiatry* 2009; 194(6): 535–540.
94. McCabe C, Mishor Z, Cowen PJ, Harmer CJ. *Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment*. *Biol. Psychiatry* 2010; 67(5): 439–445.
95. Weber M, Talmon S, Schulze I, Boeddinghaus C, Gross G, Schoemaker H et al. *Running wheel activity is sensitive to acute treatment with selective inhibitors for either serotonin or norepinephrine reuptake*. *Psychopharmacology* 2009; 203(4): 753–762.
96. Harrison AA, Markou A. *Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: Involvement of serotonin-1A receptors*. *J. Pharmacol. Exp. Ther.* 2001; 297(1): 316–325.
97. Browne CJ, Fletcher PJ. *Decreased incentive motivation following knockout or acute blockade of the serotonin transporter: Role of the 5-HT 2C receptor*. *Neuropsychopharmacology* 2016; 41(10): 2566–2576.
98. Ahrens T, Frankhauser P, Lederbogen F, Deuschle M. *Effect of single-dose sertraline on the hypothalamus-pituitary-adrenal system, autonomic nervous system, and platelet function*. *J. Clin. Psychopharmacol.* 2007; 27(6): 602.
99. Attenburrow M-J, Mitter P, Whale R, Terao T, Cowen P. *Low-dose citalopram as a 5-HT neuroendocrine probe*. *Psychopharmacology* 2001; 155(3): 323–326.
100. Holsboer F, Barden N. *Antidepressants and hypothalamic-pituitary-adrenocortical regulation*. *Endocr. Rev.* 1996; 17(2): 187–205.
101. Jensen JB, Jessop DS, Harbuz MS, Mørk A, Sánchez C, Mikkelsen JD. *Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats*. *J. Neuroendocrinol.* 1999; 11(6): 465–471.
102. Meltzer HY, Simonovic M, Sturgeon RD, Fang VS. *Effect of antidepressants, lithium and electroconvulsive treatment on rat serum prolactin levels*. *Acta. Psychiatr. Scand.* 1981; 63(s290): 100–121.
103. Moncek F, Duncko R, Jezova D. *Repeated citalopram treatment but not stress exposure attenuates hypothalamic-pituitary-adrenocortical axis response to acute citalopram injection*. *Life Sci.* 2003; 72(12): 1353–1365.
104. Seifritz E, Baumann P, Müller MJ, Annen O, Amey M, Hemmeter U et al. *Neuroendocrine effects of a 20-mg citalopram infusion in healthy males*. *Neuropsychopharmacology* 1996; 14(4): 253–263.
105. Kapitany T, Schindl M, Schindler SD, Heßelmann B, Füreder T, Barnas C et al. *The citalopram challenge test in patients with major depression and in healthy controls*. *Psychiatry Res.* 1999; 88(2): 75–88.
106. Nikisch G, Mathé AA, Czernik A, Thiele J, Bohner J, Eap CB et al. *Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: Relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response*. *Psychopharmacology* 2005; 181(4): 751–760.
107. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. *Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration*. *PLoS Medicine* 2008; 5(2): e45.

108. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC et al. *Antidepressant drug effects and depression severity: A patient-level meta-analysis*. JAMA 2010; 303(1): 47–53.
109. Moncrieff J, Kirsch I. *Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences*. Contemp. Clin. Trials 2015; 43: 60–62.
110. Shew WL, Pleniz D. *The functional benefits of criticality in the cortex*. Neuroscientist 2013; 19(1): 88–100.
111. Meunier CNJ, Chameau P, Fossier PM. *Modulation of synaptic plasticity in the cortex needs to understand all the players*. Front. Synaptic Neurosci. 2017; 9: 2. Doi: 10.3389/fnsyn.2017.00002.
112. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA. *Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice*. Science 2004; 306(5697): 879–881.
113. Amsterdam JD, Lorenzo-Luaces L, DeRubeis RJ. *Step-wise loss of antidepressant effectiveness with repeated antidepressant trials in bipolar II depression*. Bipolar Disord. 2016; 18(7): 563–570.
114. Amsterdam JD, Shults J. *Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?* J. Affect. Disord. 2009; 115(1): 234–240.
115. Amsterdam JD, Shults J. *MAOI efficacy and safety in advanced stage treatment-resistant depression—A retrospective study*. J. Affect. Disord. 2005; 89(1): 183–188.
116. Hagihara H, Ohira K, Miyakawa T. *Transcriptomic evidence for immaturity induced by antidepressant fluoxetine in the hippocampus and prefrontal cortex*. Neuropsychopharmacol. Rep. 2019; 39(2): 78–89.
117. Kobayashi K, Ikeda Y, Sakai A, Yamasaki N, Haneda E, Miyakawa T et al. *Reversal of hippocampal neuronal maturation by serotonergic antidepressants*. PNAS 2010; 107(18): 8434–8439.
118. Beshara S, Beston BR, Pinto JGA, Murphy KM. *Effects of fluoxetine and visual experience on glutamatergic and GABAergic synaptic proteins in adult rat visual cortex*. eNeuro. 2016; 2(6). Doi: 10.1523/ENEURO.0126-15.2015.
119. Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, Pasquale RD, O’Leary OF et al. *The antidepressant fluoxetine restores plasticity in the adult visual cortex*. Science 2008; 320(5874): 385–388.
120. Mitchell PJ. *Antidepressant treatment and rodent aggressive behaviour*. Eur. J. Pharmacol. 2005; 526(1): 147–162.
121. Grillon C, Chavis C, Covington MF, Pine DS. *Two-week treatment with the selective serotonin reuptake inhibitor citalopram reduces contextual anxiety but not cued fear in healthy volunteers: A fear-potentiated startle study*. Neuropsychopharmacology 2009; 34(4): 964–971.
122. de Foubert G, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA et al. *Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment*. Neuroscience 2004; 128(3): 597–604.
123. Khundakar AA, Zetterström TSC. *Biphasic change in BDNF gene expression following antidepressant drug treatment explained by differential transcript regulation*. Brain Res. 2006; 1106(1): 12–20.
124. Bianchi M, Shah AJ, Fone KCF, Atkins AR, Dawson LA, Heidbreder CA et al. *Fluoxetine administration modulates the cytoskeletal microtubular system in the rat hippocampus*. Synapse 2009; 63(4): 359–364.
125. Cai X, Kallarackal AJ, Kvarita MD, Goluskin S, Gaylor K, Bailey AM et al. *Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression*. Nat. Neurosci. 2013; 16(4): 464–472.

126. Gerdelat-Mas A, Loubinoux I, Tombari D, Rascol O, Chollet F, Simonetta-Moreau M. *Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects*. *Neuroimage* 2005; 27(2): 314–322.
127. Loubinoux I, Tombari D, Pariente J, Gerdelat-Mas A, Franceries X, Cassol E et al. *Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer*. *Neuroimage* 2005; 27(2): 299–313.

Address: Paul W. Andrews
Department of Psychology, Neuroscience & Behaviour
McMaster University
1280 Main Street West
Hamilton, ON, Canada
e-mail: pandrews@mcmaster.ca

Supplementary Material

Table S1. Empirically based statements from researchers suggesting that serotonin is elevated in depression or that adaptations to ADMs are responsible for the antidepressant effect.

Serotonin is elevated in depression	
<p>“These data implicate a <i>5HT excess</i> in extracellular space” in response to inescapable shock. And, “some evidence points to a possible 5HT excess in depression.”</p>	<p>Petty et al. (1994, pp. 289-290, emphasis in original)¹</p>
<p>“[I]ncreased <i>5-HT</i> levels in specific brain regions might reflect depressive disorder.”</p>	<p>Zangen et al. (1997, pp. 2479-2480, emphasis in original)²</p>
<p>“The marked reduction in serotonin turnover following SSRI treatment and the accompanying improvement in symptoms suggest that high brain serotonin turnover may be a biological substrate of MDD.”</p>	<p>Barton et al. (2008, p. 38)³</p>

Detailed description of study by Trouvin et al. (1993)⁴

In a study by Trouvin and colleagues, rats were treated with fluoxetine for three weeks.⁴ After the drug was discontinued, the rats were followed for varying periods of time and then sacrificed to measure serotonin and 5-HIAA concentrations in four brain regions—hippocampus, cortex, hypothalamus, and pons medulla (Figures S1 and S2).




Figure S1. Data are from Trouvin et al. (1993).⁴ Rats were exposed to fluoxetine at 10, 20 or 30 mg/kg/day (i.p.) for 21 days, after which the drug was discontinued. The rats were followed for up to varying lengths of times after discontinuation (1, 3, 7, 14, 21, and 28 days), sacrificed, and then several brain regions (hippocampus and cerebral cortex shown here) were assayed for

serotonin (5-HT) and 5-hydroxy-indoleacetic acid (5-HIAA) content. The ratio of 5-HIAA/5-HT was calculated from this data. Day “0” represents the levels of the variables over 21 days of i.p. injection of saline. Since it was the control where no fluoxetine was administered, it represents the baseline.




Figure S2. Data for the hypothalamus and the pons medulla are from Trouvin et al. (1993).⁴ See the Figure S2 legend for other details.

In Figures S1 and S2, day “0” represents the average levels of the variables over 21 days of intraperitoneal injection of saline. It can be considered the premedication baseline. Day “1”

represents the system one day after the drug had been discontinued. Based on the half-life data for fluoxetine and its active metabolite (norfluoxetine) in rats,⁵ the rats barely had enough time to eliminate most of the drug from their body by Day “1”. (At least this would be true of the 10 mg/kg/day dose. The higher dosages may have taken longer to metabolize.) In other words, the system did not have much time to re-equilibrate, so the serotonin content at that time is probably close to the value that had equilibrated over the course of chronic fluoxetine treatment. Thus, it appears that for most fluoxetine dosages in all four brain regions, chronic fluoxetine treatment resulted in a decline in total serotonin brain content, consistent with the other research described in the paper.

By day 3, nearly all of the fluoxetine and norfluoxetine should have been metabolized. As the SERT sites in each brain region became unblocked, extracellular serotonin should have declined as it re-entered the pre-synaptic neurons. This could explain why there was often a further drop in serotonin content at day 3 in most brain regions. However, by day 7, serotonin content started to increase and eventually returned to the pre-drug (day 0) baseline value. In other words, the loss of serotonin content that occurred during chronic fluoxetine administration was eventually reversed after the drug was discontinued, and this presumably involved an upregulation in the synthesis of serotonin.

The researchers did not report the 5-HIAA/5-HT ratio, but they did report 5-HIAA and 5-HT concentrations separately, which allowed for the calculation of the ratio (Figures S1 and S2). The day 1 baseline value represents the system shortly after fluoxetine had been discontinued and it shows that serotonin neurotransmission has been suppressed (relative to the unmedicated

baseline) in all four brain regions. This is consistent with research discussed in the main text (see Figure 3). However, as fluoxetine clears from the system by day 3, serotonin transmission increases. The increase in transmission, coupled with the increase in synthesis, must have helped return forebrain serotonin concentrations to normal.

Other results in this study are worth noting. First, after discontinuation, serotonin neurotransmission exhibited an overshoot, which is consistent with our hormetic predictions. Second, in three of the four brain regions, the largest serotonin overshoot occurred at the highest fluoxetine dose, which is also consistent with our predictions. Third, in all four regions, the greater the dose, the more delayed the overshoot. Although unexpected, it is consistent with our predictions. Finally, after the overshoot, there appears to be a gradual decline in serotonin transmission, and it eventually returned to pre-fluoxetine, baseline conditions.

References

- 1 Petty F, Kramer G, Wilson L, Jordan S. In vivo Serotonin release and learned helplessness. *Psychiatry Res* 1994; **52**: 285–93.
- 2 Zangen A, Overstreet DH, Yadid G. High Serotonin and 5-Hydroxyindoleacetic Acid Levels in Limbic Brain Regions in a Rat Model of Depression; Normalization by Chronic Antidepressant Treatment. *J Neurochem* 1997; **69**: 2477–83.
- 3 Barton DA, Esler MD, Dawood T, *et al.* Elevated brain serotonin turnover in patients with depression: Effect of genotype and therapy. *Arch Gen Psychiatry* 2008; **65**: 38–46.
- 4 Trouvin JH, Gardier AM, Chanut E, Pages N, Jacquot C. Time course of brain serotonin metabolism after cessation of long-term fluoxetine treatment in the rat. *Life Sci* 1993; **52**: PL187–92.
- 5 Qu Y, Aluisio L, Lord B, *et al.* Pharmacokinetics and pharmacodynamics of norfluoxetine in rats: Increasing extracellular serotonin level in the frontal cortex. *Pharmacol Biochem Behav* 2009; **92**: 469–73.